Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
J Med Case Rep. 2020 Nov 9;14(1):214. doi: 10.1186/s13256-020-02531-5.
Hyperhomocysteinemia is caused by genetic and environmental factors, which can result in systemic arteriosclerosis and arteriovenous thrombosis including acute coronary syndrome. Thrombus burden in patients with acute coronary syndrome and hyperhomocysteinemia might involve the culprit lesion as compared with those without any coagulopathy. The primary percutaneous coronary intervention with stent implantation had been established as the treatment strategy for patients with acute coronary syndrome. However, in patients with acute coronary syndrome with high thrombus burden or uncontrolled coagulopathy, stent implantation might lead to slow-flow phenomenon or stent thrombosis. Therefore, the treatment strategy in these patients was not established.
A 49-year-old Japanese man with history of splenic infarction of unknown cause had continued anticoagulant therapy since its diagnosis, but stopped taking the medication several months ago. He presented with sudden-onset chest dorsalgia. Contrast computed tomography showed a small pulmonary embolism and his troponin I level was elevated on initial laboratory test. Coronary angiography revealed a contrast defect caused by a large thrombus from the proximal to mid portion of the left anterior descending artery. Near-infrared spectroscopy-intravascular ultrasonography showed a large amount of thrombus without lipid plaque. Therefore, revascularization was performed using a thrombus-aspiration catheter and intracoronary thrombolysis. In addition, , hyperhomocysteinemia and a deep vein thrombosis occurred. He was diagnosed with acute coronary syndrome complicated with pulmonary embolism and deep vein thrombosis simultaneously induced by hyperhomocysteinemia. After 1 week of antithrombotic therapy, near-infrared spectroscopy-intravascular ultrasonography and optical coherence tomography revealed a decreased thrombus and no significant residual organic stenosis in the left anterior descending artery. He continued conservative therapy with antithrombotic medications including aspirin and warfarin and had no cardiovascular events after discharge. Follow-up coronary angiography and optical coherence tomography at 9 months revealed complete disappearance of the thrombus and no severe stenosis.
Hyperhomocysteinemia should be considered as a cause of arterial vein thrombosis of unknown cause. The antithrombotic therapy and percutaneous revascularization without stenting based on intravascular imaging might be a safe and effective treatment option in patients with acute coronary syndrome complicated with hyperhomocysteinemia.
高同型半胱氨酸血症由遗传和环境因素引起,可导致包括急性冠状动脉综合征在内的全身动脉硬化和动静脉血栓形成。与无任何凝血功能障碍的患者相比,急性冠状动脉综合征合并高同型半胱氨酸血症患者的血栓负荷可能涉及罪犯病变。经皮冠状动脉介入治疗联合支架植入术已被确立为急性冠状动脉综合征患者的治疗策略。然而,对于急性冠状动脉综合征且血栓负荷较高或凝血功能未得到控制的患者,支架植入可能导致慢血流现象或支架内血栓形成。因此,这些患者的治疗策略尚未确定。
一位 49 岁的日本男性,曾因不明原因的脾梗死而持续接受抗凝治疗,但数月前停止了用药。他突发胸痛。对比增强计算机断层扫描显示存在小范围肺栓塞,且初始实验室检查发现肌钙蛋白 I 水平升高。冠状动脉造影显示左前降支近段至中段存在由大血栓导致的造影剂缺损。近红外光谱血管内超声显示存在大量血栓,而无脂质斑块。因此,采用血栓抽吸导管和冠状动脉内溶栓进行血运重建。此外,还发现高同型半胱氨酸血症和深静脉血栓形成。该患者被诊断为急性冠状动脉综合征,同时合并由高同型半胱氨酸血症引起的肺栓塞和深静脉血栓形成。在进行 1 周的抗凝治疗后,近红外光谱血管内超声和光学相干断层扫描显示血栓减少,左前降支无明显残留的器质性狭窄。该患者继续接受包括阿司匹林和华法林在内的抗血栓药物保守治疗,出院后无心血管事件发生。9 个月时的冠状动脉造影和光学相干断层扫描随访显示血栓完全消失,无严重狭窄。
高同型半胱氨酸血症应被视为不明原因的动静脉血栓形成的一个病因。对于急性冠状动脉综合征合并高同型半胱氨酸血症的患者,基于血管内影像学的抗血栓治疗和无支架的经皮血运重建可能是一种安全有效的治疗选择。